Non-Tuberculous Mycobacterial (NTM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Non-Tuberculous Mycobacterial (NTM) Market Outlook

Thelansis’s “Non-Tuberculous Mycobacterial (NTM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Non-Tuberculous Mycobacterial treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Non-Tuberculous Mycobacterial (NTM) Overview

Non-tuberculosis mycobacterial (NTM) lung infections, while less common than those caused by Mycobacterium tuberculosis, are transmitted via inhaled aerosolized droplets containing the infectious agents. Risk factors for NTM transmission include close living quarters, coughing, and failure to wear masks. Advanced age, immunosuppression, and corticosteroid use raise the risk of acquiring NTM microorganisms. Once inside the body, NTM microorganisms primarily settle in the lower airways, leading to an inflammatory response characterized by an influx of lymphocytes. This immune reaction releases cytokines and other mediators, resulting in pneumonia-like symptoms, including fever, weight loss, night sweats, decreased appetite, and energy loss. The prognosis of NTM lung infections is uncertain, particularly for immunocompromised patients. The prognosis may also vary based on the specific NTM infection type. Research suggests that Mycobacterium avium complex (MAC) infections have a more favorable prognosis, while Mycobacterial abscessus lung infections have higher mortality rates. Chronic underlying lung diseases, particularly Mycobacterial abscessus infection and the specific NTM infection type are significant predictors of mortality. NTM lung disease typically presents in three major clinical forms: fibro-cavitary, nodular bronchiectasis, and hypersensitivity pneumonitis, with clinical manifestations often resembling other lung infections and chronic diseases.

• In the USA, the incidence of NTM is estimated at 4.73 cases per 100,000 annually.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: